CL2022000085A1 - Método para aislar genes tcr - Google Patents

Método para aislar genes tcr

Info

Publication number
CL2022000085A1
CL2022000085A1 CL2022000085A CL2022000085A CL2022000085A1 CL 2022000085 A1 CL2022000085 A1 CL 2022000085A1 CL 2022000085 A CL2022000085 A CL 2022000085A CL 2022000085 A CL2022000085 A CL 2022000085A CL 2022000085 A1 CL2022000085 A1 CL 2022000085A1
Authority
CL
Chile
Prior art keywords
tcr genes
catalogs
tcr
isolating
isolating tcr
Prior art date
Application number
CL2022000085A
Other languages
English (en)
Spanish (es)
Inventor
Antonius Nicolaas Maria Schumacher
Carsten Linnemann
Thomas Kuilman
Gavin M Bendle
Jules F C Gadiot
Heijst Jeroen W J Van
Raquel Gomez-Eerland
Deborah Sophie Schrikkema
Original Assignee
Neogene Therapeutics B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neogene Therapeutics B V filed Critical Neogene Therapeutics B V
Publication of CL2022000085A1 publication Critical patent/CL2022000085A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ecology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
CL2022000085A 2019-07-15 2022-01-12 Método para aislar genes tcr CL2022000085A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962874125P 2019-07-15 2019-07-15
US202062975924P 2020-02-13 2020-02-13
US202063024341P 2020-05-13 2020-05-13
US202063034157P 2020-06-03 2020-06-03
US202063039346P 2020-06-15 2020-06-15

Publications (1)

Publication Number Publication Date
CL2022000085A1 true CL2022000085A1 (es) 2022-09-20

Family

ID=74211262

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000085A CL2022000085A1 (es) 2019-07-15 2022-01-12 Método para aislar genes tcr

Country Status (12)

Country Link
US (1) US20210040558A1 (enExample)
EP (1) EP3999528A4 (enExample)
JP (1) JP2022541181A (enExample)
KR (1) KR20220075210A (enExample)
CN (1) CN114502579A (enExample)
AU (1) AU2020315325A1 (enExample)
BR (1) BR112022000790A2 (enExample)
CA (1) CA3146845A1 (enExample)
CL (1) CL2022000085A1 (enExample)
MX (1) MX2022000667A (enExample)
TW (1) TW202117014A (enExample)
WO (1) WO2021011482A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3428194T (pt) 2017-07-14 2021-11-18 Immatics Biotechnologies Gmbh Molécula de polipéptido com especificidade dupla melhorada
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
KR20230065251A (ko) 2020-08-07 2023-05-11 네오진 테라퓨틱스 비.브이. 유전적으로 조작된 t 세포를 풍부화시키기 위한 방법
KR20230146538A (ko) 2021-01-20 2023-10-19 네오진 테라퓨틱스 비.브이. 조작된 항원 제시 세포
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
WO2023010436A1 (zh) * 2021-08-05 2023-02-09 卡瑞济(北京)生命科技有限公司 Tcr表达构建体以及其制备方法和用途
WO2023114994A1 (en) * 2021-12-16 2023-06-22 Board Of Regents, The University Of Texas System Personalized ranking and identification of onco-reactive t cell receptors and uses thereof
CN114134221B (zh) * 2022-01-28 2022-04-08 北京肿瘤医院(北京大学肿瘤医院) 一种筛选肿瘤特异tcr的方法
WO2023183344A1 (en) * 2022-03-21 2023-09-28 Alaunos Therapeutics, Inc. Methods for identifying neoantigen-reactive t cell receptors
CN115341020A (zh) * 2022-08-29 2022-11-15 深圳市美星生物科技有限公司 一种利用lamp技术的急性心梗和心衰外显子测序方法
EP4638712A2 (en) * 2022-12-22 2025-10-29 Bluesphere Bio, Inc. Methods for identifying t cell receptors (tcrs) that bind antigens
WO2024163607A2 (en) * 2023-02-02 2024-08-08 Board Of Regents, The University Of Texas System T-cell receptors targeting egfr and methods of use thereof
JP2025076403A (ja) * 2023-10-31 2025-05-15 テンパス エーアイ，インコーポレイテッド Ｔ細胞受容体のスクリーニング方法
WO2025213105A1 (en) * 2024-04-04 2025-10-09 Biontech Us Inc. Methods for identifying t-cell receptor (tcr) sequences
WO2025240737A1 (en) * 2024-05-16 2025-11-20 Rutgers, The State University Of New Jersey Methods of producing memory t cells in vitro and their use in immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2895509T3 (da) * 2012-09-14 2020-03-09 Us Health T-cellereceptorer, som genkender mhc-klasse ii begrænset mage-a3
EP4636401A2 (en) * 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
AU2017271128A1 (en) * 2016-05-25 2019-01-03 The Council Of The Queensland Institute Of Medical Research Immune checkpoint inhibitors and cytotoxic t cells for the treatment of cancer
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors

Also Published As

Publication number Publication date
EP3999528A1 (en) 2022-05-25
MX2022000667A (es) 2022-07-21
WO2021011482A1 (en) 2021-01-21
JP2022541181A (ja) 2022-09-22
CN114502579A (zh) 2022-05-13
AU2020315325A1 (en) 2022-02-17
US20210040558A1 (en) 2021-02-11
BR112022000790A2 (pt) 2022-04-12
TW202117014A (zh) 2021-05-01
CA3146845A1 (en) 2021-01-21
EP3999528A4 (en) 2023-10-25
KR20220075210A (ko) 2022-06-07

Similar Documents

Publication Publication Date Title
Berlin et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy
Bassani-Sternberg et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry
Sahin et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sucker et al. Genetic evolution of T-cell resistance in the course of melanoma progression
CL2021002997A1 (es) Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535)
Braga et al. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells
Gubin et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Suen et al. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade
Biran et al. Senescent cells communicate via intercellular protein transfer
Cai et al. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients
Viel et al. Monitoring NK cell activity in patients with hematological malignancies
MX2022000667A (es) Metodo para aislar genes tcr.
Pieren et al. Response kinetics reveal novel features of ageing in murine T cells
MX2021005013A (es) Métodos para la selección y estimulación de células y aparatos para los mismos.
MX2019013184A (es) Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.
Paret et al. CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer
Klar et al. Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells
Laske et al. Alternative variants of human HYDIN are novel cancer-associated antigens recognized by adaptive immunity
EP4248980A3 (en) T-cell expansion method and uses
Pritchard et al. Exploration of peptides bound to MHC class I molecules in melanoma
Eisenberg et al. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells
de Sousa et al. Targeting neoepitopes to treat solid malignancies: immunosurgery
Nabbi et al. Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours
Zikich et al. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma
Han et al. Streamlined selection of cancer antigens for vaccine development through integrative multi-omics and high-content cell imaging